These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 12568401

  • 1. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
    Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM.
    J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
    [Abstract] [Full Text] [Related]

  • 2. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.
    Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tató L.
    J Pediatr; 1996 Sep; 129(3):432-9. PubMed ID: 8804334
    [Abstract] [Full Text] [Related]

  • 4. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M.
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [Abstract] [Full Text] [Related]

  • 5. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C, Rauch F, Travers R, Glorieux FH.
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
    King D, Jarjoura D, McEwen HA, Askew MJ.
    J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
    [Abstract] [Full Text] [Related]

  • 9. Alendronate treatment in osteogenesis imperfecta.
    Madenci E, Yilmaz K, Yilmaz M, Coskun Y.
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [Abstract] [Full Text] [Related]

  • 10. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
    Chlebna-Sokol D, Rusinska A.
    Endocr Regul; 2001 Dec; 35(4):201-8. PubMed ID: 11858767
    [Abstract] [Full Text] [Related]

  • 11. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA, Peacock M.
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [Abstract] [Full Text] [Related]

  • 12. In vitro expression of osteoblastic markers in cells isolated from normal fetal and postnatal human bone and from bone of patients with osteogenesis imperfecta.
    Mörike M, Schulz M, Brenner RE, Bushart GB, Teller WM, Vetter U.
    J Cell Physiol; 1993 Dec; 157(3):439-44. PubMed ID: 8253854
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
    Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA.
    J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
    [Abstract] [Full Text] [Related]

  • 15. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [Abstract] [Full Text] [Related]

  • 16. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA, Ford L, McClintock C, Peacock M.
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
    Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R.
    J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.